Lineaz Indications/Uses

Linezolid is active against most gram positive bacteria including MRSA, streptococci and VRE. The drug approved for the treatment of VRE infections.
Linezolid is a not preferred agent in treatment of infections requiring prolonged therapy (i.e. > 2 weeks) due to the risk of serious hematologic and neurologic toxicity. Use of Linezolid is generally reserved for treatment of infections due to drug-resistant organisms (e.g. MRSA, VRE).
Community-acquired pneumonia: Treatment of community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae, including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).
Nosocomial pneumonia (hospital-acquired or healthcare-associated pneumonia): Treatment of nosocomial pneumonia (hospital-acquired or healthcare-associated pneumonia) caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae.
Uncomplicated skin and skin structure infections: Treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes.
Complicated skin and skin structure infections (including diabetic foot infections), without concurrent osteomyelitis: Treatment of complicated skin and skin structure infections (including diabetic foot infections), without concurrent osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae. The use of linezolid in the treatment of decubitus ulcers has not been studied.
Vancomycin-resistant Enterococcus faecium (VRE) infections: Treatment of vancomycin-resistant Enterococcus faecium (VRE) infections, including cases with concurrent bacteremia.